Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome

Molecular Autism
Hyeong-Min LeeBenjamin D Philpot

Abstract

Angelman syndrome (AS) is a severe neurodevelopmental disorder lacking effective therapies. AS is caused by mutations in ubiquitin protein ligase E3A (UBE3A), which is genomically imprinted such that only the maternally inherited copy is expressed in neurons. We previously demonstrated that topoisomerase I (Top1) inhibitors could successfully reactivate the dormant paternal allele of Ube3a in neurons of a mouse model of AS. We also previously showed that one such Top1 inhibitor, topotecan, could unsilence paternal UBE3A in induced pluripotent stem cell-derived neurons from individuals with AS. Although topotecan has been well-studied and is FDA-approved for cancer therapy, its limited CNS bioavailability will likely restrict the therapeutic use of topotecan in AS. The goal of this study was to identify additional Top1 inhibitors with similar efficacy as topotecan, with the expectation that these could be tested in the future for safety and CNS bioavailability to assess their potential as AS therapeutics. We tested 13 indenoisoquinoline-derived Top1 inhibitors to identify compounds that unsilence the paternal allele of Ube3a in mouse neurons. Primary cortical neurons were isolated from embryonic day 14.5 (E14.5) mice with a Ube3...Continue Reading

References

Apr 1, 1993·American Journal of Medical Genetics·J L ZackowskiC A Williams
Feb 1, 1996·Pediatric Neurology·S SteffenburgM Kyllerman
Sep 1, 1997·Nature Genetics·T H Vu, A R Hoffman
Feb 13, 1999·Journal of Medicinal Chemistry·D StrumbergM Cushman
Apr 1, 1999·Cancer Chemotherapy and Pharmacology·S A El-Gizawy, M A Hedaya
Dec 18, 2001·The Oncologist·L BomgaarsS M Blaney
Feb 5, 2003·Journal of Medical Genetics·J Clayton-Smith, L Laan
Jan 26, 2005·Brain & Development·Charles A Williams
Apr 2, 2005·Journal of Medicinal Chemistry·Bart L StakerAlex B Burgin
Aug 25, 2006·Clinical Pharmacokinetics·Susannah MotlClinton F Stewart
Sep 9, 2006·Cancer Treatment Reviews·Charles FuchsPaulo M Hoff
Sep 23, 2006·Nature Reviews. Cancer·Yves Pommier
Oct 13, 2006·Journal of Medicinal Chemistry·Muthukaman NagarajanMark Cushman
Nov 2, 2006·Genome Biology·Anne E CarpenterDavid M Sabatini
May 13, 2008·Expert Review of Anticancer Therapy·Lynn Feun, Niramol Savaraj
Oct 3, 2008·Neuropsychiatric Disease and Treatment·Karine PelcBernard Dan
Apr 23, 2009·Molecular Cancer Therapeutics·Yves Pommier, Mark Cushman
Oct 7, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert J KindersUNKNOWN National Cancer Institute Phase 0 Clinical Trials Team
Nov 26, 2010·Pediatric Blood & Cancer·Jane E MinturnJean B Belasco
Apr 13, 2011·Journal of Neurodevelopmental Disorders·Benjamin D PhilpotCharles A Williams
May 20, 2011·Trends in Neurosciences·Angela M MabbBenjamin D Philpot
Dec 23, 2011·Nature·Hsien-Sung HuangBenjamin D Philpot
Dec 25, 2013·Handbook of Clinical Neurology·Riccardo SoffiettiRoberta Rudà
Nov 19, 2014·Proceedings of the National Academy of Sciences of the United States of America·Angela M MabbMark J Zylka
Sep 24, 2015·Nature Reviews. Clinical Oncology·Jacqueline B Stone, Lisa M DeAngelis
Oct 21, 2016·Nature Reviews. Molecular Cell Biology·Yves PommierJohn L Nitiss

❮ Previous
Next ❯

Citations

Apr 2, 2019·Current Topics in Medicinal Chemistry·Wenjie Wang, Yuk-Ching Tse-Dinh
Feb 23, 2020·The FEBS Journal·Carina MarangaSimão Teixeira da Rocha
Aug 21, 2020·Learning & Memory·Maria N Schultz, Jacqueline N Crawley
Jan 10, 2020·Current Gene Therapy·Christos TsagkarisAmrit Dhar
Feb 24, 2020·Neuroscience·Diana C RotaruYpe Elgersma
Mar 20, 2021·Scientific Reports·Dilara SenAlbert J Keung
May 29, 2021·Annals of Clinical and Translational Neurology·Lauren M OstrowskiCatherine J Chu
Jun 12, 2021·Expert Opinion on Investigational Drugs·Theodora MarkatiLaurent Servais

❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis

Clinical Trials Mentioned

NCT01051635

Software Mentioned

CellProfiler

Related Concepts

Related Feeds

Angelman Syndrome

Angelman syndrome is a neurogenetic imprinting disorder caused by loss of the maternally inherited UBE3A gene and is characterized by generalized epilepsy, limited expressive speech, sleep dysfunction, and movement disorders. Here is the latest research.